Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 15;23(4):84.
doi: 10.1208/s12248-021-00617-6.

Evaluation of Microparticulate (S)-4,5-Dihydroxy-2,3-pentanedione (DPD) as a Potential Vaccine Adjuvant

Devyani Joshi  1 , Christiane Chbib  2 , Mohammad N Uddin  1 , Martin J D'Souza  3
Affiliations

Evaluation of Microparticulate (S)-4,5-Dihydroxy-2,3-pentanedione (DPD) as a Potential Vaccine Adjuvant

Devyani Joshi et al. AAPS J. .

Abstract

Adjuvants potentiate the immune response against co-inoculated antigens in the vaccine formulation. Based on the mechanism of action, the adjuvants are classified as immunostimulatory adjuvants and vaccine delivery systems. (S)-4,5-Dihydroxy-2,3-pentanedione (DPD) is the precursor of bacterial quorum sensing molecule, autoinducer (AI)-2. We tested the immunogenicity and adjuvant potential of microparticulate formulation of (S)-DPD via in vitro evaluation. By formulating the microparticles of (S)-DPD, we consolidated the advantages of both the classes of adjuvants. The microparticulate (S)-DPD was tested for its immunogenicity and cytotoxicity. We further tested its adjuvant effect by combining it with particulate vaccines for measles and gonorrhea and compared the adjuvant effect observed with the microparticulate formulations of the FDA-approved adjuvants alum, MPL A®, and MF59®. Microparticulate (S)-DPD was found to be non-cytotoxic towards the antigen-presenting cells and had an adjuvant effect with microparticulate gonorrhea vaccine. Further studies with additional bacterial vaccines and the in vivo evaluation will confirm the potential of microparticulate (S)-DPD as a probable vaccine adjuvant candidate.

Keywords: (S)-DPD; adjuvant; immunostimulatory; microparticle; quorum sensing.

PubMed Disclaimer

References

    1. Edelman R. The development and use of vaccine adjuvants [Internet]. In: Vol. 21, Applied Biochemistry and Biotechnology - Part B Molecular Biotechnology: Springer; 2002. p. 129–48. [cited 2020 Nov 29]. Available from: https://link.springer.com/article/10.1385/MB:21:2:129 .
    1. Singh M, O’Hagan DT. Recent advances in vaccine adjuvants. Pharm Res. 2002;19(6):715–28. - DOI
    1. Adjuvant | Definition of Adjuvant by Merriam-Webster [Internet]. [cited 2020 Nov 29]. Available from: https://www.merriam-webster.com/dictionary/adjuvant
    1. Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752–62. - DOI
    1. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: putting innate immunity to work [Internet]. In: Vol. 33, Immunity. Immunity; 2010. p. 492–503. [cited 2020 Nov 29] Available from: https://pubmed.ncbi.nlm.nih.gov/21029960/ .

LinkOut - more resources